Spexis 宣布向 Basilea 出售临床前抗生素项目。 Spexis announces sale of preclinical antibiotics program to Basilea.
瑞士生物制药公司 Spexis 宣布将其临床前抗生素项目出售给 Basilea。 Swiss biopharmaceutical company Spexis has announced the sale of its preclinical antibiotics program to Basilea. 该计划包括针对革兰氏阴性细菌（包括多重耐药菌株）的新型抗生素。 The program consists of novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains. 临床前研究表明，抗生素在体外和体内对多种革兰氏阴性菌均表现出杀菌活性。 Preclinical studies have shown the antibiotics to exhibit bactericidal activity against a broad range of Gram-negative bacteria both in vitro and in vivo. Basilea 将为该计划支付高达 200 万瑞士法郎，这是 Spexis 合作或剥离非核心计划和资产的努力的一部分，因为该公司仍处于暂停状态。 Basilea will pay up to CHF 2 million for the program, which is part of Spexis' efforts to partner or divest non-core programs and assets as the company remains under a moratorium.